Eisai Executives Warns U.K.'s NICE To Change Approval System
This article was originally published in PharmAsia News
Executive Summary
Eisai Deputy President Yutaka Tsuchiya warned the U.K.'s drug-regulating body that if it does not improve its drug-registering process, the Japan-based company would reduce planned investments in the country.